Biodesix Inc is a biotechnology company that specializes in providing diagnostic solutions primarily for patients with lung diseases, particularly lung cancer. The company focuses on developing and commercializing innovative blood-based tests that enable clinicians to make more informed decisions regarding the diagnosis, prognosis, and treatment of lung cancer. Their comprehensive suite of tests leverages advanced genomics and artificial intelligence to analyze biomarkers, helping to tailor personalized treatment plans for patients and improve overall outcomes. Through its commitment to precision medicine, Biodesix aims to enhance patient care in oncology by delivering actionable insights that guide therapy choices. Read More
Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer
Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific
LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2025 after the close of trading on Monday, November 3. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company’s common stock will continue to trade under Biodesix’s existing trading symbol, BDSX, on the Nasdaq Global Market (“Nasdaq”) on a split-adjusted basis when the market opens on Monday, September 15, 2025, with the new CUSIP number 09075X207.
LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference on Thursday, September 11, 2025.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
